Investment
Features
FeesSafety
Academy
More
Pluang+

Compare F5 Inc (FFIV) vs Pfizer Inc (PFE) Price & Performance

F5 IncTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

F5 Inc vs Pfizer Inc — how do they compare? F5 Inc trades at $402.02 (market cap $23.79B), while Pfizer Inc trades at $25.28 (market cap $141.46B). The key difference: Pfizer Inc is far larger — about 5.9× F5 Inc's market cap, and Pfizer Inc pays a 6.93% dividend while F5 Inc pays none. Which is the better fit depends on your goals.

FFIVPFE
Market Cap
$23.79B$141.46B
Sector
TechnologyHealth
52-Week High
$431.26$28.56
52-Week Low
$223.99$23.29
Enterprise Value
$22.60B$192.12B
Volume
29,869,932
Dividend Yield
6.93%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

F5 Inc

F5 Networks (FFIV) trades at $419.00, down 2.84% on the day, but remains in a bullish technical trend above key support levels. The company demonstrates strong fundamental momentum with revenue growth to $3.09B in 2025 and consistent earnings beats, including a recent Q1 2026 EPS of $3.90 against a $3.46 expectation. Recent news highlights strategic expansion into AI security, including the acquisition of SurePath AI (GeekWire, 2026-06-26).

The outlook is supported by robust profitability and strategic positioning in application security, but elevated valuation multiples (P/E 34.61, P/S 7.6) and a high current price relative to the analyst consensus target of $397.00 present near-term valuation risk. The primary investment opportunity lies in the company's execution on its AI security platform growth, while risks include competitive pressures and the stock's premium pricing.

Pfizer Inc

Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.

Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.

Returns comparison

Trailing returns across standard periods

About F5 Inc

F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.

Read more on FFIV

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE